1 Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, and.
2 Rutgers Institute for Translational Medicine and Science, Child Health Institute, Rutgers University, New Brunswick, New Jersey; and.
Am J Respir Cell Mol Biol. 2018 May;58(5):575-584. doi: 10.1165/rcmb.2017-0247OC.
Transforming growth factor β1 (TGF-β1), a cytokine whose levels are elevated in the airways of patients with asthma, perpetuates airway inflammation and modulates airway structural cell remodeling. However, the role of TGF-β1 in excessive airway narrowing in asthma, or airway hyperresponsiveness (AHR), remains unclear. In this study, we set out to investigate the direct effects of TGF-β1 on human airway smooth muscle (HASM) cell shortening and hyperresponsiveness. The dynamics of AHR and single-cell excitation-contraction coupling were measured in human precision-cut lung slices and in isolated HASM cells using supravital microscopy and magnetic twisting cytometry, respectively. In human precision-cut lung slices, overnight treatment with TGF-β1 significantly augmented basal and carbachol-induced bronchoconstriction. In isolated HASM cells, TGF-β1 increased basal and methacholine-induced cytoskeletal stiffness in a dose- and time-dependent manner. TGF-β1-induced single-cell contraction was corroborated by concomitant increases in myosin light chain and myosin phosphatase target subunit 1 phosphorylation levels, which were attenuated by small interfering RNA-mediated knockdown of Smad3 and pharmacological inhibition of Rho kinase. Strikingly, these physiological effects of TGF-β1 occurred through a RhoA-independent mechanism, with little effect on HASM cell [Ca] levels. Together, our data suggest that TGF-β1 enhances HASM excitation-contraction coupling pathways to induce HASM cell shortening and hyperresponsiveness. These findings reveal a potential link between airway injury-repair responses and bronchial hyperreactivity in asthma, and define TGF-β1 signaling as a potential target to reduce AHR in asthma.
转化生长因子β1(TGF-β1)是一种细胞因子,其在哮喘患者的气道中水平升高,可使气道炎症持续存在,并调节气道结构细胞重塑。然而,TGF-β1 在哮喘中过度气道狭窄或气道高反应性(AHR)中的作用尚不清楚。在这项研究中,我们着手研究 TGF-β1 对人气道平滑肌(HASM)细胞缩短和高反应性的直接作用。使用超活显微镜和磁扭转细胞术分别在人精密肺切片和分离的 HASM 细胞中测量 AHR 和单细胞兴奋-收缩偶联的动力学。在人精密肺切片中,TGF-β1 过夜处理显著增强了基础和乙酰甲胆碱诱导的支气管收缩。在分离的 HASM 细胞中,TGF-β1 以剂量和时间依赖性方式增加基础和乙酰甲胆碱诱导的细胞骨架硬度。TGF-β1 诱导的单细胞收缩通过肌球蛋白轻链和肌球蛋白磷酸酶靶亚基 1 磷酸化水平的同时增加得到证实,这可以通过 Smad3 的小干扰 RNA 介导的敲低和 Rho 激酶的药理学抑制来减弱。引人注目的是,TGF-β1 的这些生理作用是通过一种 RhoA 独立的机制发生的,对 HASM 细胞 [Ca]水平的影响很小。总之,我们的数据表明,TGF-β1 增强 HASM 兴奋-收缩偶联途径,诱导 HASM 细胞缩短和高反应性。这些发现揭示了哮喘中气道损伤修复反应与支气管高反应性之间的潜在联系,并将 TGF-β1 信号定义为减少哮喘中 AHR 的潜在靶点。